DEPLOYDatabase

Company

Moon Surgical

Surgical-robotics company (Paris + San Carlos CA; CEO Anne Osdoit, chair Fred Moll) making the Maestro laparoscopic surgical-assistant robot with the shipped…

Track Moon Surgical
Founded
2020
HQ
San Carlos, California, USA
Status
private (~$90M+ raised; NVentures-backed)

The verified answer

As of Aug 2026, DEPLOY verifies Moon Surgical: 1 model. 4 sources back the record.

Regulatory status2 FDA 510(k) clearances

Moon Surgical holds 2 FDA 510(k) clearances, per the DEPLOY registry.

See all 2 filings

CategorySurgical robots

Models

1

Overview

Surgical-robotics company (Paris + San Carlos CA; CEO Anne Osdoit, chair Fred Moll) making the Maestro laparoscopic surgical-assistant robot with the shipped FDA-cleared ScoPilot AI (NVIDIA Holoscan).

Verified record

Verified deployments
None on file
Active incidents
None on file

Key facts

Product

Maestro laparoscopic surgical-assistant robot + ScoPilot shipped AI scope-control.

Gating events

Maestro FDA 510(k) K240598 Jun 5 2024; ScoPilot FDA-cleared 2025 with PCCP.

CEO

Anne Osdoit

Chair

Fred Moll

Additional office location

Paris, France

ScoPilot AI platform

NVIDIA Holoscan

Data & sources

Press releases

1

Government records

1

Web sources

2

4 sources backing this record.View all →

Models (1)

View all models →

Current platform

Maestro

Moon Surgical (private, with offices in Paris and San Carlos, California; led by CEO Anne Osdoit, with Intuitive Surgical co-founder Fred Moll as board chair and backers including Sofinnova Partners and NVIDIA's venture arm NVentures) makes Maestro, a laparoscopic surgical-assistant and collaboration robot that holds and positions instruments and the endoscope alongside the surgeon rather than acting as a full master-slave teleoperation console, targeting the large pool of soft-tissue procedures unserved by teleoperated robots. The commercial Maestro received FDA 510(k) clearance under K240598 on June 5, 2024, and the company reports more than 1,100 patients treated across the US and Europe, on roughly $90 million-plus in funding. A notable AI distinction in this cohort: Maestro's ScoPilot is a genuinely shipped, FDA-cleared AI feature for intraoperative scope control, powered by NVIDIA Holoscan and cleared with a Predetermined Change Control Plan, rather than a mere demonstration, which sets Maestro apart from the teleoperation-only platforms here. A pathway correction worth recording: Maestro went the 510(k) route under K240598, not the de novo route sometimes assumed, with the contemporaneous de novo authorizations belonging to different companies such as Virtual Incision and MMI. The registry records Maestro at commercial maturity, an early-commercial collaborative-assist robot past its gating event, while noting that its CE mark status, exact installed-system count, and the more-than-1,100-patients figure are not independently verified.

surgicalView model →

Moon Surgical on the deployment map

View the global map

Moon Surgical has no verified deployments on the DEPLOY registry yet. Explore the deployment map by place and type.

Free to use on your site, with a link back to DEPLOY.

No verified deployments for Moon Surgical on the DEPLOY record yet. Track Moon Surgical to know the moment the first one is verified.

Free to use on your site, with a link back to DEPLOY.

Relationships

SSofinnova PartnersInvestorOOrbiMedInvestorSSectoral Asset ManagementInvestor

Explainers

Plain-language answers to the questions people ask about Moon Surgical, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

What is a surgical robot?
A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.Read the full explainer →
What is Moon Surgical Maestro?
Moon Surgical Maestro is the Maestro Laparoscopy Co-Pilot, an FDA-cleared ASSISTIVE (NOT replacement) robotic system for laparoscopic procedures from Moon Surgical, a French-US dual-base company founded 2020. Per DEPLOY's surgical cluster framework: FDA 510(k) K240598 cleared June 2024 (primary-source FDA database verification). EDITORIAL DISTINCTION: assistive-laparoscopy positioning. Maestro augments surgeons within existing laparoscopic procedures rather than replacing them as full surgical platforms (Intuitive da Vinci, Medtronic Hugo, CMR Versius, J&J Ottava). Smaller-footprint OR integration + commercial-niche positioning. Per DEPLOY's surgical cluster framework, Maestro is the cohort's genuine shipped assistive-AI exemplar within the broader replacement-robotics cluster. Cohort positioning: assistive-laparoscopy commercial-niche archetype within the surgical cluster, extending the cluster's structural axes from FDA-clearance-posture (Wave 1) into clinical-domain + commercial-model variance (Wave 2).Read the full explainer →
How did DEPLOY correct the Moon Maestro FDA clearance date?
DEPLOY's Moon Maestro entity anchor originally framed FDA 510(k) clearance as 'December 2023 (specific K-number at cap-flag pending primary-source confirmation).' The framing was honest cap-flag discipline at the time: month-precision claim with K-number explicitly held at cap-flag pending primary-source-anchored verification. Primary-source FDA database research per Agent A surfaces K240598 cleared June 2024. Both the K-number resolves (K240598) AND the date was off by six months (June 2024, not December 2023). The reconciliation operates as a worked example of DEPLOY's verified-vs-claimed framework applied recursively to DEPLOY's own corpus: cap-flag-honestly until primary source confirms; update + surface the change transparently via inline editorial-transparency footer + framework-in-action correction narrative when primary source surfaces. The catch is the discipline operating on itself. Per DEPLOY's framework discipline, recursive application of cap-flag + primary-source-anchored verification on DEPLOY's own published corpus + transparent surfacing of correction in entity-anchor footer + canonical worked-example narrative at correction-tier depth compounds editorial credibility at the operational-practice layer.Read the full explainer →
How does DEPLOY think about robot insurance?
DEPLOY thinks about robot insurance as a four-dimension actuarial framework operating recursively across the verified-vs-claimed throughline: deployment-incident-recall actuarial depth (61 verified incidents at primary-source-anchored severity + root-cause + regulatory-action depth; exposure denominators absent at most deployments); manufacturer financial-state / counterparty risk (114 investors + 58 funding rounds + 29 acquisitions verified; financial state vs relationship state distinction); supply-chain component failure analysis (absent as structured substrate; bounded to safety-critical components when authored); regulatory clearance per jurisdiction (34 verified filings lopsided 94% US-FDA-only; jurisdictional completeness is the load-bearing gating layer for insurability per region). The discipline that distinguishes DEPLOY's framework from the broader insurance-discourse cohort: honest 'insurability unknown for this region / no exposure data' is more valuable than a fabricated rate. Cap-flag-as-trust-signal operates recursively on actuarial framing.Read the full explainer →

Current leadership (2)

Founders (2)

See all founders across the registry →

Board (1)

Safety record

No incidents on record for Moon Surgical.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Recent coverage

Moon Surgical in third-party press

Moon Surgical wins first FDA 510(k) clearance for surgical robot

Jun 25, 2026

Moon Surgical wins FDA clearance for Maestro

Jun 1, 2025

Peer companies